Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

6
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
6
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

324
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
324
Liver Regeneration01:24

Liver Regeneration

4.7K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.7K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

278
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatic thermal injury promotes colorectal cancer engraftment in C57/black 6 mice.

American journal of physiology. Cell physiology·2020
Same author

Research in academic medical centers: two threats to sustainable support.

Science translational medicine·2015
Same author

Increased phosphoenolpyruvate carboxykinase gene expression and steatosis during hepatitis C virus subgenome replication: role of nonstructural component 5A and CCAAT/enhancer-binding protein β.

The Journal of biological chemistry·2012
Same author

Copper inhibits P2Y(2)-dependent Ca(2+) signaling through the effects on thapsigargin-sensitive Ca(2+) stores in HTC hepatoma cells.

Biochemical and biophysical research communications·2010
Same author

Initiation of purinergic signaling by exocytosis of ATP-containing vesicles in liver epithelium.

The Journal of biological chemistry·2010
Same author

Report of the Multisociety Task Force on GI training.

Gastrointestinal endoscopy·2009
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Hepatology after Hepatitis C.

J Gregory Fitz1

  • 1UT Southwestern Medical Center, Dallas, Tex., USA.

Digestive Diseases (Basel, Switzerland)
|June 23, 2016
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) treatments are successful, but global challenges remain. Future advances in hepatology will focus on early detection and treatment of liver disease, particularly in high-risk populations.

More Related Videos

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

5.8K
Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

3.8K

Related Experiment Videos

Last Updated: Mar 19, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K
Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
10:04

Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice

Published on: December 2, 2022

5.8K
Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
05:25

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

3.8K

Area of Science:

  • Hepatology and viral hepatitis research.
  • Genetics and personalized medicine in liver disease.
  • Public health and global disease burden.

Background:

  • Direct-acting antivirals offer high cure rates for Hepatitis C virus (HCV), but global access and cost limit impact.
  • Liver disease incidence and mortality are increasing worldwide, making hepatology crucial.
  • Current successes in HCV treatment highlight the need for broader liver disease management strategies.

Purpose of the Study:

  • To outline future directions in hepatology beyond Hepatitis C virus (HCV) treatment.
  • To emphasize the importance of early identification and intervention for liver diseases.
  • To explore the role of genomics and personalized medicine in managing liver conditions.

Main Methods:

  • Review of current landscape in hepatology and liver disease management.
  • Analysis of global disease burden and treatment access for viral hepatitis.
  • Exploration of genetic risk factors, such as PNPLA3 gene variants.
  • Discussion of emerging strategies for fibrosis, cancer, and cirrhosis detection and treatment.

Main Results:

  • Hepatitis C virus (HCV) eradication is unlikely in the near future due to global disparities.
  • PNPLA3 gene variants are common and increase susceptibility to liver injury from various causes.
  • Early detection of fibrosis and hepatoma using biomarkers is critical for effective treatment.
  • Future treatments will likely focus on anti-fibrotic strategies and liver regeneration.

Conclusions:

  • Hepatology must evolve to address the rising global burden of liver disease.
  • Genomic insights and personalized approaches, like targeting PNPLA3, are key for early risk identification.
  • Investing in hepatology is essential for developing next-generation treatments and improving patient outcomes.